Project Vikas to enhance efficiency of around 1,000 A'bad-based pharma SMEs
Pharmaceutical manufacturing clusters in Ahmedabad received a booster dose in form of the National Manufacturing Competitiveness Council (NMCC) and Microsoft India's joint initiative 'Project Vikas', aimed at building their skill and increasing efficiency and reliability. Under this project, launched in Gujarat on Wednesday, Microsoft India will provide support through its customised software to around 1,000 Ahmedabad-based small and medium scale units engaged in pharma sector.
The announcement by Aurobindo Pharma to enter in to a strategic deal with US-based pharmaceutical major Pfizer helped its shares price on the Bombay Stock Exchange on Wednesday. The deal would allow selling of generic medicines, used for cardiovascular disease and central nervous system disorders, in the US and European market.
The global generic market is currently worth $270 billion and expected to grow over $500 billion in the next five years. Pfizer holds considerable shares in drug market, selling $10 billion non-exclusive drug annually.
Washington - The US Supreme Court ruled Wednesday that patients can sue drugmakers for failing to warn adequately of serious side effects, even if their warning labels were approved by the federal government, according to a landmark case that could expose the industry to billions of dollars in damages.
In a 6-3 decision, the court upheld a 7-million-dollar reward to a professional musician whose arm had to be amputated after she was improperly injected with Phenergan, an anti-nausea drug produced by pharmaceutical firm Wyeth.
The US Food and Drug Administration (USFDA) has given tentative approval to Aurobindo Pharma, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), to market Escitalopram Oxalate tablets in variable strengths.
Aurbindo will market the pills in dosages of 5mg, 10mg and 20mg.
Aurobindo Pharma, one of the largest API manufacturers in Asia, has in
The announcement by Aurobindo Pharma to enter in to a strategic deal with US-based pharmaceutical major Pfizer helped its shares price on the Bombay Stock Exchange on Wednesday. The deal would allow selling of generic medicines, used for cardiovascular disease and central nervous system disorders, in the US and European market.
Washington - The US Supreme Court ruled Wednesday that patients can sue drugmakers for failing to warn adequately of serious side effects, even if their warning labels were approved by the federal government, according to a landmark case that could expose the industry to billions of dollars in damages.
The US Food and Drug Administration (USFDA) has given tentative approval to Aurobindo Pharma, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), to market Escitalopram Oxalate tablets in variable strengths.
